Marinus Verwijs is CTO at Aerovate Therapeutics, Inc. (AVTE). They have made 4 open-market trades across 1 company since 2022, most recently 2024-06-14.
CIK 0001916553
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AVTE | 10,600 | $28K |
Shares reported on the most recent Form 4, priced at the 2024-06-14 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AVTE | SELL · 10b5-1 | 2024-06-14 | 2024-06-14 | $25.00 | $265K | -30.7% | -21.2% | -22.0% |
| AVTE | SELL | 2024-05-02 | 2024-05-03 | $21.02 | $42K | +3.0% | -14.9% | -91.2% |
| AVTE | SELL · 10b5-1 | 2024-04-01 | 2024-04-03 | $29.06 | $264K | -14.6% | -31.5% | -94.5% |
| AVTE | SELL · 10b5-1 | 2024-03-19 | 2024-03-20 | $26.09 | $277K | +12.9% | -15.8% | -94.6% |
| AVTE | SELL | 2023-11-01 | 2023-11-03 | $10.46 | $10K | +25.4% | +42.7% | +60.8% |
| AVTE | SELL | 2023-05-03 | 2023-05-05 | $20.79 | $16K | -10.9% | -27.0% | -24.5% |
| AVTE | SELL | 2022-11-02 | 2022-11-03 | $18.89 | $21K | +1.1% | -6.5% | +19.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.